ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · IEX Real-Time Price · USD
6.15
-0.46 (-6.96%)
At close: Jul 19, 2024, 4:00 PM
6.44
+0.29 (4.72%)
Pre-market: Jul 22, 2024, 7:33 AM EDT
ALX Oncology Holdings Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ALXO stock have an average target of 20.5, with a low estimate of 14 and a high estimate of 27. The average target predicts an increase of 233.33% from the current stock price of 6.15.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 10, 2024.
Analyst Ratings
The average analyst rating for ALXO stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +306.50% | Jun 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 29, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +225.20% | Apr 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +225.20% | Mar 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.95
from -3.74
EPS Next Year
-2.90
from -2.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 22.4M | 147.2M | 454.3M |
| Avg | n/a | n/a | 9.0M | 82.9M | 244.0M |
| Low | n/a | n/a | n/a | 15.1M | 67.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,531.2% | 447.9% |
| Avg | - | - | - | 819.2% | 194.3% |
| Low | - | - | - | 67.3% | -18.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.69 | -2.24 | -1.96 | -2.97 | 0.18 |
| Avg | -2.95 | -2.90 | -2.88 | -2.89 | 0.17 |
| Low | -3.10 | -3.27 | -3.59 | -2.77 | 0.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.